Champions Oncology, Inc. (CSBR) 股票分析

公司概述

Champions Oncology, Inc. operates as a technology-enabled research company that specializes in providing advanced technology solutions for drug discovery and development within the United States market. Through its proprietary Tumorgraft technology platform, the firm delivers personalized cancer care methodologies by utilizing the implantation of human tumors within immune-deficient models to facilitate therapeutic research. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on innovative biological products and high-risk, high-reward research activities. With a current market capitalization of $79.85M, annual revenue of $57.95M, and an employee count of 213, the company maintains a relatively small scale typical of mid-stage biotechnology firms. These financial figures indicate that the entity possesses a moderate market presence but operates with limited revenue generation relative to its valuation, suggesting a company still in a phase where research and development expenditures likely outweigh immediate profitability.

财务健康

The company reported a trailing twelve-month revenue of $57.95M, while recording a net income of $-2,343,000 and an EBITDA of $-772,000. The significant negative gap between the $57.95M revenue and the negative net income reveals a cost structure where operational expenses and research costs substantially exceed gross profit margins. Despite the reported losses, the company maintains a free cash flow of $4.70M, which provides a critical layer of financial flexibility by generating liquidity internally to fund ongoing operations without immediate reliance on external equity financing. The gross margin stands at 45.9%, indicating that the company retains nearly half of its revenue after direct production costs, yet this is insufficient to cover overheads. The operating margin is -1.1% and the profit margin is -4.0%, reflecting that the company is currently burning cash on a per-dollar-of-sales basis due to high fixed costs associated with biotechnology research. In terms of leverage, the company holds $7.13M in cash against $5.00M in debt, resulting in a debt-to-equity ratio of 114.19, which suggests a leveraged balance sheet where liabilities slightly exceed shareholder equity. The current ratio of 0.98 indicates that current assets are marginally lower than current liabilities, pointing to potential short-term liquidity pressure. Furthermore, the return on equity is -47.6% and the return on assets is -4.7%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the company's asset base.

估值评估

The stock exhibits a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is 57.50, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio is 18.67, which indicates that the market values the company at a significant premium over its tangible book value, a common characteristic for biotechnology firms with valuable intellectual property. Alternative valuation metrics include a price-to-sales ratio of 1.38 and an EV/EBITDA of -100.80, suggesting that investors are valuing the firm primarily on its sales growth potential rather than earnings power. The stock has traded between a 52-week high of $9.63 and a 52-week low of $5.50, with the current trading price situated within this historical volatility range. The beta value of 0.40 indicates that the stock's price volatility is substantially lower than the broader market, offering a profile of reduced systematic risk compared to larger-cap equities.

Growth & Income

Revenue growth year-over-year is -2.8%, while earnings growth is N/A given the negative net income, indicating that the company is currently contracting in terms of sales rather than expanding. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available resources into research and development rather than distributing income to shareholders. The absence of a dividend payout is sustainable in this context as the company retains earnings to support its R&D pipeline despite the negative profit margin. Overall, the growth and income profile is characterized by negative sales growth and zero dividend distribution, typical for a biotechnology company focused on long-term drug development cycles rather than immediate financial returns.